MRK logo

MERCK & CO. INC.

MRKNYSE
πŸ† #34 by market capEarnings Feb 2 Β· PreUS Equity
$133.70β–² $0.97 (+0.73%)
Market closed Β· at close
πŸ””
Track MRK
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.7%
7dβ–Ό 9.5%
14dβ–Ό 8.9%
30dβ–Ό 8.0%
ytdβ–² 27.0%
1yβ–² 36.8%
🏦Market Cap
$329.86B
Large Cap
πŸ“ˆRevenue Growth (YoY)
4.9%
Slowing
πŸ“ŠGross Margin
76.6%
High
πŸ’΅FCF Margin
21.9%
Strong
βš–οΈP/S Ratio
4.9x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$133.12 – $137.14
52-Week Range
$93.90 – $156.92
Volume (shares)
864,664
Avg Volume (shares)
β€”
Shares Outstanding
2.47B
Next Earnings
2027-02-02

Fundamentals Snapshot

Annual Revenue
$64.93B
Last Q Revenue
$18.09B
P/E Ratio
133.5
P/S Ratio
4.9x
EPS (TTM)
$0.98
Dividend Yield
2.56%
Dilution (1yr)
βˆ’2.1%
MRK logo

MERCK & CO. INC.

MRK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$64.9Bβ–² +1.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.0%β–Ό βˆ’5.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$23.5Bβ–² +16.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$12.4Bβ–Ό βˆ’31.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.49Bβ–Ό βˆ’2.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36.0Bβ–Ό βˆ’$10.9B YoY
StockOtter Β· stockotter.space

About MERCK & CO. INC.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100

Analyst Ratings

β“˜
Consensus
Buy
35 analysts
Strong Buy8
Buy17
Hold10
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.